CJEU asked to resolve long-standing SPC marketing authorisation conundrum
Europe’s highest court has never ruled on whether certificates can be acquired on the basis of a third-party marketing approval – a practice that has given rise to disputes between biopharma innovators
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.